FrancisJ.GilesMD

PubMed

• 2 citations
  Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.
  Queralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, Núria Lupión-Garcia, Alba Llop-Guevara, Cristina Molina, Maria Vila-Casadesús, Anthony Turpin, Cindy Neuzill...> ;Clinical Cancer Research. 2023 Jan 17
• 12 citations
  Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3...
  Gary Shaw, Ludimila Cavalcante, Francis J Giles, Alison Taylor> ;Journal of Hematology & Oncology. 2022 Sep 14
• 3 citations
  Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death.
  Chaoyuan Kuang, Jingshan Tong, Kaylee Ermine, Manbo Cai, Fujun Dai, Suisui Hao, Francis Giles, Yi Huang, Jian Yu, Lin Zhang> ;Frontiers in Oncology. 2022 Jan 1
• 1 citations
  Correction: Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-mediated DNA Damage Response.
  Li Ding, Vijay S Madamsetty, Spencer Kiers, Olga Alekhina, Andrey Ugolkov, John Dube, Yu Zhang, Jin-San Zhang, Enfeng Wang, Shamit K Dutta, Daniel M Schmitt, Francis J...> ;Clinical Cancer Research. 2021 Jul 15
• 9 citations
  The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells
  Noortje van Gils, Tania Martiañez Canales, Eline Vermue, Arjo Rutten, Fedor Denkers, Tiem van der Deure, Gert J. Ossenkoppele, Francis J. Giles, Linda Smit> ;Hemasphere. 2021 Jul 8
• 39 citations
  Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
  Jerald P. Radich, Andreas Hochhaus, Tamás Masszi, Andrzej Hellmann, Jesper Stentoft, María Teresa Gómez Casares, J. Valentín García-Gutiérrez, Eibhlin Conneally, Phili...> ;Leukemia. 2021 Mar 11
• 103 citations
  A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.
  Priya Kumthekar, Caroline H. Ko, Tatjana Paunesku, Karan Dixit, Adam M. Sonabend, Orin Bloch, Matthew C. Tate, Margaret Schwartz, Laura Zuckerman, Ray Lezon, Rimas V. ...> ;Science Translational Medicine. 2021 Mar 10
• 42 citations
  Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
  Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp le Coutre, Bjørn Tore Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel K...> ;Journal of Hematology & Oncology. 2021 Feb 24
• 11 citations
  Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in c...
  Andrew D.J. Pearson, Steven G. DuBois, Vickie Buenger, Mark W. Kieran, Kimberly Stegmaier, Pratiti Bandopadhayay, Kelly Bennett, Franck Bourdeaut, Patrick A. Brown, Lo...> ;European Journal of Cancer. 2021 Mar 1
• 16 citations
  Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in Multiple Myeloma
  Katie R. Ryan, Francis J. Giles, Gareth J. Morgan> ;European Journal of Haematology. 2021 Jan 1
• 4 citations
  The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer
  Brittany A. Borden, Yasmine Baca, Joanne Xiu, Fabio Tavora, Ira Winer, Benjamin A. Weinberg, Ari M. Vanderwalde, Sourat Darabi, W. Michael Korn, Andrew P. Mazar, Franc...> ;Molecular Cancer Therapeutics. 2021 Jan 1
• 34 citations
  Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.
  Filippo Spriano, Eugenio Gaudio, Luciano Cascione, Chiara Tarantelli, Federica Melle, Giovanna Motta, Valdemar Priebe, Andrea Rinaldi, Gaetanina Golino, Afua Adjeiwaa ...> ;Blood Advances. 2020 Sep 8
• 43 citations
  Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer
  Rajita Vatapalli, Vinay Sagar, Yara Rodriguez, Jie Zhao, Kenji Unno, Sahithi Pamarthy, Barbara Lysy, Jonathan F. Anker, Huiying Han, Young Yoo, Mihai I. Truica, Zachar...> ;Nature Communications. 2020 Aug 19
• 47 citations
  Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
  Andreas Hochhaus, Carlo Gambacorti-Passerini, Camille N. Abboud, Bjørn Tore Gjertsen, Tim H. Brümmendorf, B. Douglas Smith, Thomas Ernst, Pilar Giraldo-Castellano, Ull...> ;Leukemia. 2020 Jun 22
• 15 citations
  Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer.
  Tsutomu Anraku, Hiroo Kuroki, Akira Kazama, Vladimir Bilim, Masaaki Tasaki, Daniel Schmitt, Andrew P. Mazar, Francis J. Giles, Andrey Ugolkov, Yoshihiko Tomita> ;International Journal of Molecular Medicine. 2019 Dec 12
• 174 citations
  A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
  Sandip Pravin Patel, Megan Othus, Young Kwang Chae, Francis J. Giles, Donna E. Hansel, Preet Paul Singh, Annette Fontaine, Manisha Shah, Anup Kasi, Tareq Al Baghdadi, ...> ;Clinical Cancer Research. 2020 May 15
• 42 citations
  Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
  Chevaun Morrison-Smith, Tatiana M. Knox, Ivona Filic, Kara M. Soroko, Benjamin K. Eschle, Margaret K. Wilkens, Prafulla C. Gokhale, Francis J. Giles, Griffin Andrew, B...> ;Molecular Cancer Therapeutics. 2020 Jan 1
• 26 citations
  9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer.
  Hiroo Kuroki, Tsutomu Anraku, Akira Kazama, Vladimir Bilim, Masayuki Tasaki, Daniel Schmitt, Andrew P. Mazar, Francis J. Giles, Andrey Ugolkov, Yoshihiko Tomita> ;Scientific Reports. 2019 Dec 27
• 29 citations
  Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
  Ann Jeffers, Wenyi Qin, Shuzi Owens, Kathleen Koenig, Satoshi Komatsu, Francis J. Giles, Daniel Schmitt, Steven Idell, Torry A. Tucker> ;Scientific Reports. 2019 Dec 12
• 64 citations
  Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial
  Benedito A. Carneiro, Bhavana Konda, R. Costa, Ricardo Costa, Vinay Sagar, Demirkan B. Gursel, Lawrence S. Kirschner, Young Kwang Chae, Sarki A. Abdulkadir, Alfred Rad...> ;The Journal of Clinical Endocrinology and Metabolism. 2019 Dec 1
• 35 citations
  Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia
  Georg-Nikolaus Franke, Jacqueline Maier, Kathrin Wildenberger, Michael Cross, Francis J. Giles, Martin C. Müller, Andreas Hochhaus, Dietger Niederwieser, Thoralf Lange> ;The Journal of Molecular Diagnostics. 2020 Jan 1
• 50 citations
  The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
  Yuqian Yan, Jian Ma, Dejie Wang, Dong Lin, Xiaodong Pang, Shangqian Wang, Yu Zhao, Lei Shi, Hui Xue, Yunqian Pan, Jun Zhang, Claes Wahlestedt, Francis J Giles, Yu Chen...> ;EMBO Molecular Medicine. 2019 Nov 7
• 34 citations
  Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
  Li Ding, Vijay S Madamsetty, Spencer Kiers, Olga Alekhina, Andrey Ugolkov, John Dube, Yu Zhang, Jin-San Zhang, Enfeng Wang, Shamit K Dutta, Daniel M Schmitt, Francis J...> ;Clinical Cancer Research. 2019 Nov 1
• 54 citations
  Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
  Naseema Gangat, Christian Marinaccio, Ronan Swords, Justin M. Watts, Sandeep Gurbuxani, Alfred Rademaker, Angela J. Fought, Olga Frankfurt, Jessica K. Altman, Qiang Je...> ;Clinical Cancer Research. 2019 Aug 15
• 36 citations
  Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma
  Xiaosheng Wu, Mary Stenson, Jithma P. Abeykoon, Kevin E. Nowakowski, Lianwen Zhang, Joshua Lawson, Linda Wellik, Ying Li, Jordan E. Krull, Kerstin Wenzl, Anne J. Novak...> ;Blood. 2019 Jul 25
• Join now to see all

Abstracts/Posters

• Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
  Frank Giles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial
  Francis J. Giles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
  Frank Giles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia
  Frank Giles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib
  Francis J. Giles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from t... 
  2019 ASCO Annual Meeting - 6/1/2019